Core Viewpoint - Via Biotechnology (01873) reported a decrease in revenue for the six months ending June 30, 2025, while showing an increase in net profit attributable to shareholders [1] Financial Performance - Revenue for the period was 832 million RMB, representing a year-on-year decrease of 15.27% [1] - Net profit attributable to shareholders was 122 million RMB, reflecting a year-on-year increase of 4.28% [1] - Basic earnings per share were 0.06 RMB [1] Profitability Metrics - The group's gross profit margin was 40.8%, which is an increase of 6.3 percentage points compared to the same period last year [1] - The improvement in gross profit margin is attributed to the optimization of the Langhua business structure, enhanced operational efficiency in the CRO business, and growth in new business segments [1]
维亚生物发布中期业绩 股东应占溢利1.22亿元 同比增加4.28%